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regarding the optimal revascularization strategy in patients with DES-ISR of the
UDLM.
Methods: All consecutive patients with UDLM DES-ISR between March 2002 and
December 2008, were included in this retrospective analysis. The primary end-point
of the study was a composite of all cause death, myocardial infarction (MI) and target
lesion revascularization (TLR) within 2 years, and defined as major adverse
cardiovascular events (MACE).
Results: During the study period, 457 consecutive patients with UDLM disease
underwent DES implantation. DES-ISR of UDLM occurred in 92 (16.7%) patients.
Among the DES-ISR patients with UDLM, 8 (8.7%) underwent CABG, and 84
(91.3%) underwent PCI. Among the latter, 43 (50.6%) patients underwent PCI with
POBA and 42 (49.4%) underwent PCI with DES. MACE at 2-years occured in 33
patients (33%); 1 (12.5%) in the CABG group and 32 (37.8%) in the PCI group. In the
PCI group, the incidence of restenosis was higher following PCI with POBA than with
DES (48.9% vs.21.3%, p=0.008). On multivariable analysis, independent predictors
of repeat TLR were POBA {OR 3.52, 95% CI 1.28-9.66; p=0.015} and CKD {OR
3.81, 95% CI 1.02-14.31; p=0.047}. The original use of a 2-stent strategy at the distal
bifurcation was associated with significantly higher repeat TLR at restenosis lesions
of the circumflex ostium than was the use of a 1-stent strategy (52.0% vs. 14.3%,
p=0.038).
Conclusion: Restenosis of the UDLM should be treated with DES rather than POBA.
Although an initial 2-stent strategy increases the risk of recurrent restenosis at the LCX
ostium, this finding had little prognostic impact.
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Background: As drug-eluting stents (DESs) are being used in increasingly complicated
settings, DES restenosis is no longer an uncommon phenomenon, and its optimal
treatment is not known. The aim of this study was to compare the efficacy of paclitaxel-
eluting balloon (PEB) with repeat sirolimus-eluting stent (SES) implantation for the
treatment of SES restenosis.
Methods: From June 2004 to December 2010, 221 consecutive patients with 245
lesions after revascularization for SES restenosis were enrolled. Follow-up angiogram
was obtained 6 to 8 months after procedure. All of the initial SES were implanted in
de novo lesions. We compared characteristics of patients and lesions between the two
groups (PEB for SES restenosis: PEB group, n=131, repeat SES implantation for SES
restenosis: SES group, n=114).
Results: No significant differences were observed in clinical characteristics between
the two groups. Reference diameter (RD) and minimal lumen diameter (MLD) were
similar between the two groups (RD: 2.83 +/- 0.42 mm vs 2.91 +/- 0.48 mm, p=0.2,
MLD: 0.85 +/- 0.51 mm vs 0.91 +/- 0.52 mm, p=0.4). Lesion length was longer in the
DEB group (15.5 +/- 9.0 mm vs 13.3 +/- 6.9 mm, p=0.033). Acute gain was larger in
the SES group (1.20 +/- 0.62 mm vs 1.71 +/- 0.63mm, p<0.0001). Follow-up rate was
91% (223/245 lesions). The incidence of recurrent restenosis was 19.1% in the DEB
group and 24.1% in the SES group (p=0.4). DEB group led to a significant reduction
in 6-8 month late lumen loss (0.27 +/- 0.68 mm vs 0.63 +/- 0.74 mm, p=0.0002) and
in target lesion revascularization (13.0% vs 23.2%, p=0.049) compared to SES group.
Conclusion: In patients with SES restenosis, PEB provided much better angiographic
outcomes than repeat SES implantation.
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Background: Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel has been
proven to be effective to prevent acute thrombotic complications after coronary
stenting. Current guidelines recommend 300 mg the day before PCI or 600 mg
immediately before PCI and 4 weeks of DAPT for all patients treated with bare-metal
stents and a year of DAPT for patients treated with drug-eluting stents. The drug-eluting
balloon (DEB) studies support the use of paclitaxel-eluting balloons for the treatment
of in-stent restenosis, of small coronary arteries and bifurcations lesions. We analyzed
and compared the safety, focused on the rates of acute thrombosis after DEB in 8
current DEB studies with the outcome in a clinical setting.
Methods: A retrospective review was done of 191 consecutive patients who underwent
percutaneous coronary intervention procedure with the paclitaxel eluting balloon
SeQuent™ Please at a high-volume Heart Center in Potsdam from September 2009 to
February 2011. DEB were used for the treatment of in-stent restenosis, small coronary
arteries, bifurcations lesions, de-novo lesions or other indications. The primary
evaluation was acute coronary thrombosis. All patients were pretreated with aspirin
and clopidogrel, which was continued for 4 weeks.
Results: During hospital stay none of the 191 patients (0%) had suffered from acute
coronary thrombosis in the clinical setting. In conclusion no differences in the rates of
coronary thrombosis between the different indications for DEB were found. Moreover,
none of the patients treated with the DEB only strategy had suffered from acute
thrombosis. The rate of acute thrombosis after DEB in the clinical setting is comparable
to the results in the available DEB studies.
Conclusion: The use of DEB in routine daily practice does not appear to be associated
with a higher rate of acute thrombosis.
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Background: Even DES era there are some situations associated with a high risk of
restenosis and/or stent thrombosis. We wished to assess the efficacy of a new drug-
eluting balloon (DEB) in the treatment of these situations.
Methods: 249 patients were included in this prospective multicenter (10 Spanish
centers) registry using a new DEB (3.0μg/m2 balloon surface area) in the following
situations: in-stent restenosis (ISR) (49% DES): 126; de novo lesions in small vessels
(SMV) (≤2.5mm): 104 (42% bifurcation lesions); and in patients with a
contraindication to dual anti-platelet therapy (DAT): 19. The DEB was inflated for a
minimum of 60 seconds. Dual antiplatelet therapy was recommended for at least 1
month. The only exclusion criteria were acute STEMI and cardiogenic shock.
Results: In the following table are presented the main characteristics of this population
as well as 1-year clinical outcomes (median of 12 (6-13) months). Angiographic follow-
up was completed as follow: ISR (34 patients (79.1% of follow-up completed, 6.5 ±
2.1 months) and SMV (51 patients (84% of follow-up completed, of 7.5 ± 2.9 months).
It is important to note that 6 months angiogrpahic late loss was similar in both groups
(ISR 0.31mm and SMV 0.34mm).
In the table are presented the main characteristics of the population as well as 1-year
clinical outcomes (median of 12 (6-13) months).
Conclusion: In this un-selected population at high risk of restenosis and/or stent
thrombosis the use of this new DEB, provides excellent 1-year outcomes with high
efficacy (late loss 0.31-0.34mm) and safety (stent thrombosis 0.8-1%) despite a short
duration of dual anti-platelet therapy.
www.JACC.TCTAbstracts2011
B78 JACC Vol 58/20/Suppl B  |  November 7-11, 2011  |  TCT Abstracts/POSTER/In-stent Restenosis and Drug-Eluting Balloons
P
O
S
T
E
R
S
